focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.90
Bid: 3.30
Ask: 4.50
Change: -0.10 (-2.50%)
Spread: 1.20 (36.364%)
Open: 4.00
High: 0.00
Low: 0.00
Prev. Close: 4.00
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Airline Stocks Nosedive On Air France-KLM Warning

Tue, 08th Jul 2014 10:42

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Tuesday.
-------
FTSE 100 - WINNERS
-------
Rio Tinto, up 0.9%, and Glencore, up 0.8%. The mining companies are up after Barclays upgraded its sector view to positive, from negative, saying that it believes "a number of factors are coming together that could potentially deliver a secular shift in returns from the mining sector." In the near-term, the Chinese promise of 7.5% GDP growth for 2014 implies further stimuli and a strong recovery in the second half, while US GDP growth also is expected to be strong in the second half of the year. Further ahead, the bank believes that a European recovery is "in the offing", and, while the impact of India's Prime Minister Modi is still uncertain, it is unlikely to be negative, given his ambitions to replicate China's infrastructure-led growth model. Individually, Barclays has upgraded Rio Tinto to Overweight, from Equal Weight, increasing its price target to 3,600 pence from 3,350p, while Morgan Stanley has raised its price target on Rio to 3,540 pence from 3430p.
-------
FTSE 100 - LOSERS
-------
International Consolidated Airlines Group, down 4.8%, and easyJet, down 2.6%. The airlines have fallen after Air France-KLM warned that overcapacity on some long-haul routes hitting yields, echoing a similar warning by Lufthansa last month. The Franco-Dutch airline reported a 2.9% improvement in traffic in June, with a 1.8% increase in capacity, but it has lowered its earnings before interest, tax, depreciation and amortisation target for the year as a whole as it warned about overcapacity affecting routes to North America and Asia.

Persimmon, down 2.1%, and Barratt Developments, down 1.8%. The housebuilders are underperforming for a second day in a row. On Monday a relatively positive update from Taylor Wimpey sent the sector lower, and on Tuesday a strong update from Bovis Homes has done the same. Bovis has outperformed the booming UK housing market in the first-half of the year, improving its average selling price by 11%, compared to underlying UK house prices which have gone up by 4% over the same period. Even so, the market has become used to constant forecast upgrades from the housebuilders in recent months and the most recent updates have failed to boost sector sentiment any further.

Marks & Spencer Group, down 1.6%. The retailer has reported a hefty drop in online sales for the first quarter of its financial year, which the retailer blamed on the transition to its new website platform and a cutback in promotions both online and in store. M&S reported an 8.1% fall in sales of its online business, M&S.com, for the 13 weeks to June 28. M&S management failed to give a clear reason for the sharp decline, telling journalists that the "settling in" of the new website has held back "re-registration and conversion rates". It said that fewer promotions online and in its stores also hit sales. Total sales across the group rose 2.3% in the quarter, while UK sales were up 2%, and on a like-for-like basis were up 0.3%, driven by continued strong food sales. The retailer said it remained cautious about the outlook for the business due to competition and promotional pricing in the UK retail sector, although it has seen some improvement in consumer confidence.
-------
FTSE 250 - WINNERS
-------
3i Infrastructure, up 0.4%. The company said its first-quarter portfolio income, or the dividends and interest it makes from its portfolio assets, increased by 8.9%, helped in part by a 29% increase in the value of shares in portfolio holding Adani Power Ltd. 3i Infrastructure said that portfolio income totalled GBP19.5 million between April 1 and June 30, compared with GBP17.9 million in the corresponding quarter a year earlier. During the first-quarter the company sold part of its stake in Indian thermal-power generating company Adani Power, with GBP7.4 million in distributions received by the 3i India Infrastructure Fund.
-------
FTSE 250 - LOSERS
-------
SIG, down 4.8%. The building products distributor is a big faller, even though it said it is expecting to report a strong rise in pretax profit in the first half of the year, as strong sales growth in the UK and Ireland helped offset a hit on revenue earned elsewhere due to the strength of sterling. The company warned that sales growth moderated in the last two months of the half, but kept its guidance for "good progress" for the year as a whole despite currency movements going against it. SIG said it expects to report underlying pretax profit of at least GBP40 million for the first six months of 2014, up from GBP33.6 million last year excluding the sale of its former German roofing and Miller Pattison businesses, as sales from continuing operations rose by about 6.5% to about GBP1.29 billion. It said its sales performance moderated in May and June, with like-for-like sales up 2.9% for both months combined. It blamed the stronger comparative figures for those months. It said like-for-like sales in the whole first half were up 11.5% in the UK & Ireland, 3.2% in mainland Europe, 2.1% in France and 5.1% in Germany.
-------
AIM ALL-SHARE - WINNERS
-------
Dods Group, up 18%. The information, events and publishing company has seen its shares rise after it reported a sharply narrowed loss, higher revenue, and said it would continue transforming the publishing and events operations to push up profitability. It reported a net loss of GBP1.3 million for the year to end-March, compared with a loss of GBP10.6 million in the 15 months to March 31, 2013. Revenue rose to GBP19.8 million, from GBP18.8 million for the 15 month period, and it cut administrative expenses by more than half to GBP7.3 million. Its like-for-like sales rose by 17%, or GBP2.5 million, while its gross profit margin increased to 29%, from 25%.

London Mining, up 14%. Barclays has upgraded the company to Equal Weight from Underweight, increasing its price target to 80 pence from 75p, saying that it believes the company's balance sheet stress and near-term iron ore price issues are now in the past.

Proteome Sciences, up 13%. Shares in the company have risen after it published a study along with King's College, London identifying proteins that could be used to predict the onset of Alzheimer's, a step towards developing a blood test for the disease. Proteome said that it was selecting commercial partners to combine these protein biomarkers in a blood test for the global market.

Leyshon Energy, up 12%. The energy asset company said its Pacific Asia Petroleum Ltd subsidiary has started a previously announced interim testing programme at the Zijinshan gas project in China, although it revealed that the initial programme will take longer and cost more than it had previously flagged. It said the contractor has been mobilised to the site and will start flow testing three zones in well ZJS7 shortly. The company said its partners have also committed to drilling well ZJS8 in the northern part of the licence area, the location of which will be decided after accounting for the results from the ZJS7 well.

Clontarf Energy, up 10%. The oil and gas exploration and development company, alongside Petrel Resources, said legal proceedings related to their Tano 2A exploration licence in Ghana have been temporarily adjourned for the second time in the last two weeks. It said the case has been adjourned until July 16 at the request of all parties, so that discussions can continue.

Urals Energy, up 7.8%. The company said Adler Impex SA has significantly increased its shareholding in the company after buying shares on July 3. Adler represents the interests of Roman Shvets, a Russian banker and industrialist with certain investments in the oil sector. The oil and gas exploration and production company said that Adler Impex now holds 112.6 million shares in Urals, a 44.59% stake from 25.08% previously. Shvets could not immediately comment on the decision but Urals said that Adler Impex remains supportive of Urals Energy's management and strategy.
-------
AIM ALL-SHARE - LOSERS
-------
Monitise, off 17%. The mobile banking and payments company has fallen sharply after warning that its shift to a subscription model meant revenue in its last financial year had come in below expectations and its loss for the year will be wider than the market expected. The company said its revenue in the year to end-June grew between 31% and 33%, below the 40% growth expected, due to a faster shift to its subscription model and the lower up-front revenue that entails. It said its loss before interest, tax, depreciation and amortisation will be between GBP32 million and GBP36 million, wider than a market consensus on Bloomberg for an Ebitda loss of GBP28 million. Revenue is expected to be between GBP95 million and GBP97 million.

Belgravium Technologies, down 10%. The company's shares are among the biggest fallers in the AIM All-Share index, as it reverses some of the strong gains posted Monday. Belgravium's shares jumped sharply on Monday after it said it had been approached by Trakm8 Holdings. Trakm8 Tuesday has confirmed that it has made a preliminary takeover approach to Belgravium.
-------

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
20 Nov 2013 07:52

AIM IN BRIEF: Rangers FC Appoints Graham Wallace As CEO

Read more
30 Sep 2013 09:26

Proteome Sciences Losses Widen Despite Revenue Growth; Signs USD2.1M Contract

Read more
18 Sep 2013 15:03

Proteome Expects Strong Second-Half Growth After Making Alzheimer's Progress

Read more
12 Jun 2013 11:37

Proteome Sciences to develop cancer pathway profiling assays

AIM-listed biotech group Proteome Sciences has unveiled its largest contract to date comprising a technology agreement with Thermo Fisher Scientific, to develop advanced methods to profile changes in cancer pathways. Proteome Sciences said that the contract - which it valued at £2.1m - would prov

Read more
18 Mar 2013 14:29

Proteome Sciences looks ahead with confidence

Drug developer Proteome Sciences has told investors that it expects strong revenue growth across the company's three main divisions in 2013 and said it is 'much encouraged by the prospects'. The announcement comes after the group received a positive response to the presentation of four posters tha

Read more
31 Dec 2012 12:50

STOCKS NEWS EUROPE-UK small caps closes modestly higher

The FTSE Small Caps index closes 0.1 percent higher on Monday, New Year's Eve, tracking similar modest gains by the mid caps, also up 0.1 percent, while the blue chips shed 0.5 percent after a half-day session. The small caps index has gained 24 percent over 2012, just outperforming a 22 percent adv

Read more
31 Dec 2012 10:48

Proteome delivers encouraging results from Alzheimers study

Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function. The firm said the results provide important in-vivo proof of prin

Read more
28 Sep 2012 10:46

Proteome Sciences narrows losses, bright outlook

Proteomics specialist Proteome Sciences reduced half year losses and expects second half revenues to be significantly boosted as it doubles the number of biomarker tests available from PS Biomarker Services. The group expects major licences and contracts from its proprietary biomarkers and services

Read more
18 Sep 2012 10:57

Proteome stroke test could save thousands from brain damage

Medical technology group Proteome Sciences has released details of a study into a blood test which could reduce brain damage in thousands of stroke victims. The group has been collaborating with researchers at the University of Geneva to produce the test which can tell how long ago a stroke actuall

Read more
20 Aug 2012 07:43

London pre-open: Doubts about further Chinese stimulus

City sources predict the FTSE 100 will open up five points from Friday's close of 5,852, having gained 18 points during Friday's session following positive data from the US. Over the weekend it was reported in Europe by the Handelsblatt newspaper that the European Union could appoint the European

Read more
20 Aug 2012 07:20

Proteome Sciences reports collaboration research agreement

Biotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility

Read more
5 Apr 2012 11:50

Proteome issues new licence for stroke product

Pharma group Proteome Sciences has granted a non-exclusive licence to UK firm Randox Laboratories for its portfolio of stroke biomarkers. Under the terms of the agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Proteome will ear

Read more
28 Mar 2012 10:46

Proteome rockets on Alzheimer's blood test

Pharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease. A study of 1,000 patients has shown three distinct "biomarkers" in people's blood which can discriminate between mild "cognitive

Read more
19 Mar 2012 10:17

Stroke consortium to get €11m grant

Shares in biomarker specialist Proteome Sciences rose almost 5% on Monday morning after it announced the EU was to award €11m to a consortium of which it is a member. Euro-HYP-1, a consortium of academic, clinical and industrial European partners that includes Proteome, has been awarded the grant f

Read more
27 May 2011 12:09

Proteome boosted by Sanofi settlement

Biomarker specialist Proteome Sciences is back in profit after receiving €11m from Sanofi-Aventis to settle a warranty claim. The company posted pre-tax profits of £4.59m in the year to the end of December, including the warranty claim. This compared £4.20m pre-tax loss in 2009. Revenues for 2010

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.